Table 5. PHLDA and p53 protein expression and clinicopathologic characteristics of the patients with lung cancer and malignant mesothelioma (Chi-square test; P value <0.05).
Characteristic | PHLDA1 (cell/mm2) | PHLDA2 (cell/mm2) | PHLDA3 (cell/mm2) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Low | High | P value | Low | High | P value | Low | High | P value | |||
Age (years) | 0.42 | 0.11 | 0.11 | ||||||||
>61.5 | 27 (27.6%) | 22 (22.4%) | 29 (29.6%) | 20 (20.4%) | 29 (29.6%) | 20 (20.4%) | |||||
≤61.5 | 22 (22.4%) | 27 (27.6%) | 20 (20.4%) | 29 (29.6%) | 20 (20.4%) | 29 (29.6%) | |||||
Sex | 0.09 | 1.0 | 0.09 | ||||||||
Female | 13 (13.0%) | 22 (22.0%) | 17 (17.0%) | 18 (18.0%) | 13 (13.0%) | 22 (22.0%) | |||||
Male | 37 (37.0%) | 28 (28.0%) | 33 (33.0%) | 32 (32.0%) | 37 (37.0%) | 28 (28.0%) | |||||
Tumor type | 0.42 | 0.22 | <0.01 | ||||||||
LUAD | 18 (17.6%) | 23 (22.5%) | 17 (16.7%) | 24 (23.5%) | 12 (11.8%) | 29 (28.4%) | |||||
MM | 33 (32.4%) | 28 (27.5%) | 34 (33.3%) | 27 (26.5%) | 39 (38.2%) | 22 (21.6%) | |||||
Tumor stage† | 0.61 | 0.30 | <0.01 | ||||||||
I | 7 (7.0%) | 8 (8.0%) | 7 (7.0%) | 8 (8.0%) | 3 (3.0%) | 12 (12.0%) | |||||
II | 7 (7.0%) | 7 (7.0%) | 5 (5.0%) | 9 (9.0%) | 5 (5.0%) | 9 (9.0%) | |||||
III | 1 (1.0%) | 4 (4.0%) | 2 (2.0%) | 3 (3.0%) | 1 (1.0%) | 4 (4.0%) | |||||
IV | 35 (35.0%) | 31 (31.0%) | 36 (36.0%) | 30 (30.0%) | 41 (41.0%) | 25 (25.0%) | |||||
Statusa | 0.36 | 0.20 | 0.58 | ||||||||
Alive | 13 (13.3%) | 20 (20.4%) | 12 (12.2%) | 21 (21.4%) | 17 (17.3%) | 16 (16.3%) | |||||
Dead | 34 (34.7%) | 28 (28.6%) | 35 (35.7%) | 27 (27.6%) | 30 (30.6%) | 32 (32.7%) | |||||
Overall survival | 0.28 | 0.83 | 0.83 | ||||||||
>19.9 months | 25 (29.4%) | 18 (21.2%) | 22 (25.9%) | 21 (24.7%) | 22 (25.9%) | 21 (24.7%) | |||||
≤19.9 months | 19 (22.4%) | 23 (27.1%) | 20 (23.5%) | 22 (25.9%) | 23 (27.1%) | 19 (22.4%) | |||||
p53 | 0.03 | 0.01 | <0.01 | ||||||||
≤2.9 cell/mm2 | 30 (30.6%) | 19 (19.4%) | 31 (31.6%) | 18 (18.4%) | 32 (3.7%) | 17 (17.3%) | |||||
>2.9 cell/mm2 | 18 (18.4%) | 31 (31.6%) | 18 (18.4%) | 31 (31.6%) | 18 (18.4%) | 31 (31.6%) |